|
Trinity's TriPex™ system is a proprietary fusion protein transport capability consisting of three parts: a receptor-binding and translocation segment; a hydrolysable linker; and a therapeutic payload. It works by utilizing the natural mechanism of the CD-91 receptor pathway. CD-91 receptors are expressed in intestinal mucosae and are available to facilitate the absorption of Trinity's fusion protein drugs.
Components of the TriPex™ system include:
- A carrier molecule, consisting of the receptor binding domain and translocation domain of the pseudomonas exotoxin A. This protein molecule is engineered by Trinity to eliminate its cytotoxic domain, leaving only those portions critical for its drug transport functionality.
- A hydrolysable linker specifically designed to attach the carrier molecule to the drug payload. This linker is designed to release the intact macromolecular drug upon absorption from the gastrointestinal tract.
- A therapeutic payload is a biologically active therapeutic macromolecule that is released intact from the carrier molecule and linker into the circulation upon absorption.
Once the carrier molecule binds to the CD-91 receptor, the intestinal epithelial cells naturally take up the fusion protein, which is then shuttled through the intestinal membrane and delivered into the circulation.
What differentiates this receptor-mediated transport construct from other experimental oral delivery technologies are two important attributes. First, this transport mechanism utilizes an entirely natural biological process. There is no opening or chemical disruption of the tight junctions and no damage to the epithelium. Second, this technology can be controlled and optimized. Trinity's core expertise and proprietary ownership is precisely in designing this simple but elegant system for the absorption of macromolecules from the gastrointestinal tract.
| 
)
)
